Skip to main content

Dr. Alan Tan, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
20
In the NPI registry since
2007
Medicare patients seen, 2024
109

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    TN license 70201 · IN license 01071270A

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
109
Services billed
290
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes230108
New patient office or other outpatient visit, 60-74 minutes3232
Telephone medical discussion with physician, 21-30 minutes2320
Established patient office or other outpatient visit, 30-39 minutes2219

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Orgovyx (relugolix)84
Nubeqa (darolutamide)52
Prednisone
Other prescribers in Nashville, TN
42
Abiraterone Acetate32
Xtandi (enzalutamide)15

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 13 companies reported 84 payments worth $125,610 in total to this clinician.

By company
Aveo Pharmaceuticals, Inc.$42,477
E.r. Squibb & Sons, L.l.c.$35,889
Exelixis Inc.$22,807
Pfizer Inc.$9,133
Merck Sharp & Dohme LLC$4,478
Roche Diagnostics International LTD$4,242
Astellas Pharma US Inc$3,870
Janssen Biotech, Inc.$2,348
By type
Compensation for services other than consulting (speaking, faculty)$74,615
Consulting Fee$23,160
Speaking at a medical education program$20,625
Travel and Lodging$5,180
Food and Beverage$1,987
Education$43.25

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Apr 3, 2025E.r. Squibb & Sons, L.l.c.
Apr 3, 2025
Compensation for services other than consulting (speaking, faculty)
OPDIVO · Oncology
$11,385
Jun 5, 2025Aveo Pharmaceuticals, Inc.
Jun 5, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
$7,245
Sep 23, 2025Aveo Pharmaceuticals, Inc.
Sep 23, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
Company’s descriptionSpeaker Compensation
$7,245
Oct 9, 2025Aveo Pharmaceuticals, Inc.
Oct 9, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
Company’s descriptionSpeaker Compensation
$7,245
May 27, 2025E.r. Squibb & Sons, L.l.c.
May 27, 2025
Consulting Fee$6,760
Sep 24, 2025Exelixis Inc.
Sep 24, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$4,455
Dec 3, 2025Merck Sharp & Dohme LLC
Dec 3, 2025
Compensation for services other than consulting (speaking, faculty)
KEYTRUDA · ONCOLOGY
$4,270
May 1, 2025E.r. Squibb & Sons, L.l.c.
May 1, 2025
Compensation for services other than consulting (speaking, faculty)
OPDIVO · Oncology
$3,623
May 1, 2025E.r. Squibb & Sons, L.l.c.
May 1, 2025
Compensation for services other than consulting (speaking, faculty)
OPDIVO · Oncology
$3,623
Jul 30, 2025Pfizer Inc.
Jul 30, 2025
Consulting Fee
PADCEV · ONCOLOGY
$3,000
All 65 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 23, 2025Aveo Pharmaceuticals, Inc.
Dec 23, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
Company’s descriptionSpeaker Compensation
$2,013
Dec 19, 2025E.r. Squibb & Sons, L.l.c.
Dec 19, 2025
Consulting Fee$520
Dec 9, 2025Exelixis Inc.
Dec 9, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Dec 4, 2025Roche Diagnostics International LTD
Dec 4, 2025
Consulting Fee$1,061
Dec 3, 2025Merck Sharp & Dohme LLC
Dec 3, 2025
Compensation for services other than consulting (speaking, faculty)
KEYTRUDA · ONCOLOGY
$4,270
Dec 2, 2025Merck Sharp & Dohme LLC
Dec 2, 2025
Travel and Lodging
KEYTRUDA · ONCOLOGY · travel to Paducah, KY
$150
Nov 24, 2025Pfizer Inc.
Nov 24, 2025
Consulting Fee
PADCEV · ONCOLOGY
$3,000
Nov 19, 2025Exelixis Inc.
Nov 19, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Nov 19, 2025AstraZeneca Pharmaceuticals LP
Nov 19, 2025
Education
ENHERTU · Oncology · in-kind
Company’s descriptionJournal Article
$43.25
Nov 12, 2025Astellas Pharma US Inc
Nov 12, 2025
Compensation for services other than consulting (speaking, faculty)
Padcev · Oncology
$2,580
Oct 14, 2025Exelixis Inc.
Oct 14, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Oct 9, 2025Aveo Pharmaceuticals, Inc.
Oct 9, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
Company’s descriptionSpeaker Compensation
$7,245
Oct 9, 2025Aveo Pharmaceuticals, Inc.
Oct 9, 2025
Travel and Lodging
FOTIVDA · Oncology · travel to Chicago, IL
Company’s descriptionGround Transportation OOP
$156
Oct 9, 2025Aveo Pharmaceuticals, Inc.
Oct 9, 2025
Travel and Lodging
FOTIVDA · Oncology · travel to Chicago, IL
Company’s descriptionAirfare Other OOP
$8.00
Oct 1, 2025Aveo Pharmaceuticals, Inc.
Oct 1, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
Company’s descriptionSpeaker Compensation
$2,013
Oct 1, 2025Exelixis Inc.
Oct 1, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Sep 27, 2025Aveo Pharmaceuticals, Inc.
Sep 27, 2025
Travel and Lodging
FOTIVDA · Oncology · travel to The Woodlands, TX · in-kind
Company’s descriptionAirfare
$364
Sep 27, 2025Aveo Pharmaceuticals, Inc.
Sep 27, 2025
Travel and Lodging
FOTIVDA · Oncology · travel to The Woodlands, TX · in-kind
Company’s descriptionHotel
$309
Sep 25, 2025Exelixis Inc.
Sep 25, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind
$185
Sep 25, 2025Exelixis Inc.
Sep 25, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind
$185
Sep 24, 2025Exelixis Inc.
Sep 24, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$4,455
Sep 23, 2025Aveo Pharmaceuticals, Inc.
Sep 23, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
Company’s descriptionSpeaker Compensation
$7,245
Sep 20, 2025Exelixis Inc.
Sep 20, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind
$336
Sep 20, 2025Exelixis Inc.
Sep 20, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL
$159
Sep 20, 2025Exelixis Inc.
Sep 20, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind
$70.00
Sep 20, 2025Exelixis Inc.
Sep 20, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL
$8.00
Sep 19, 2025Janssen Biotech, Inc.
Sep 19, 2025
Consulting Fee
ERLEADA · Oncology
$1,010
Sep 13, 2025Aveo Pharmaceuticals, Inc.
Sep 13, 2025
Travel and Lodging
FOTIVDA · Oncology · travel to Chicago, IL · in-kind
Company’s descriptionAirfare
$455
Aug 29, 2025Exelixis Inc.
Aug 29, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind
$478
Aug 29, 2025Exelixis Inc.
Aug 29, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind
$49.44
Aug 29, 2025Exelixis Inc.
Aug 29, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind
$49.44
Aug 19, 2025Exelixis Inc.
Aug 19, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Jul 30, 2025Pfizer Inc.
Jul 30, 2025
Consulting Fee
PADCEV · ONCOLOGY
$3,000
Jul 30, 2025Aveo Pharmaceuticals, Inc.
Jul 30, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
Company’s descriptionSpeaker Compensation
$2,013
Jul 30, 2025Aveo Pharmaceuticals, Inc.
Jul 30, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
Company’s descriptionSpeaker Compensation
$2,013
Jul 29, 2025Exelixis Inc.
Jul 29, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Jul 27, 2025Roche Diagnostics International LTD
Jul 27, 2025
Consulting Fee$530
Jul 23, 2025Aveo Pharmaceuticals, Inc.
Jul 23, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
Company’s descriptionSpeaker Compensation
$2,013
Jul 10, 2025Aveo Pharmaceuticals, Inc.
Jul 10, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
$2,013
Jul 3, 2025Astellas Pharma US Inc
Jul 3, 2025
Compensation for services other than consulting (speaking, faculty)
Padcev · Oncology
$1,290
Jul 2, 2025Roche Diagnostics International LTD
Jul 2, 2025
Consulting Fee$530
Jul 1, 2025Exelixis Inc.
Jul 1, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Jun 26, 2025Exelixis Inc.
Jun 26, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$330
Jun 18, 2025Aveo Pharmaceuticals, Inc.
Jun 18, 2025
Travel and Lodging
FOTIVDA · Oncology · travel to Orlando, FL
$74.79
Jun 5, 2025Aveo Pharmaceuticals, Inc.
Jun 5, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
$7,245
May 27, 2025E.r. Squibb & Sons, L.l.c.
May 27, 2025
Consulting Fee$6,760
May 17, 2025Aveo Pharmaceuticals, Inc.
May 17, 2025
Travel and Lodging
FOTIVDA · Oncology · travel to Orlando, FL · in-kind
$453
May 17, 2025Aveo Pharmaceuticals, Inc.
May 17, 2025
Travel and Lodging
FOTIVDA · Oncology · travel to Orlando, FL · in-kind
$303
May 8, 2025Aveo Pharmaceuticals, Inc.
May 8, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
$2,013
May 8, 2025Aveo Pharmaceuticals, Inc.
May 8, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
$2,013
May 1, 2025E.r. Squibb & Sons, L.l.c.
May 1, 2025
Compensation for services other than consulting (speaking, faculty)
OPDIVO · Oncology
$3,623
May 1, 2025E.r. Squibb & Sons, L.l.c.
May 1, 2025
Compensation for services other than consulting (speaking, faculty)
OPDIVO · Oncology
$3,623
Apr 30, 2025Aveo Pharmaceuticals, Inc.
Apr 30, 2025
Compensation for services other than consulting (speaking, faculty)
FOTIVDA · Oncology
$2,013
Apr 28, 2025Roche Diagnostics International LTD
Apr 28, 2025
Consulting Fee$1,061
Apr 28, 2025E.r. Squibb & Sons, L.l.c.
Apr 28, 2025
Consulting Fee$518
Apr 23, 2025Pfizer Inc.
Apr 23, 2025
Consulting Fee
PADCEV · ONCOLOGY
$3,000
Apr 3, 2025E.r. Squibb & Sons, L.l.c.
Apr 3, 2025
Compensation for services other than consulting (speaking, faculty)
OPDIVO · Oncology
$11,385
Mar 28, 2025Janssen Biotech, Inc.
Mar 28, 2025
Consulting Fee
ERLEADA · Oncology
$1,110
Mar 28, 2025Roche Diagnostics International LTD
Mar 28, 2025
Consulting Fee$1,061
Mar 28, 2025E.r. Squibb & Sons, L.l.c.
Mar 28, 2025
Travel and Lodging
OPDIVO · Oncology · travel to Fort Walton Beach, FL
$626
Mar 13, 2025E.r. Squibb & Sons, L.l.c.
Mar 13, 2025
Travel and Lodging
OPDIVO · Oncology · travel to Fort Walton Beach, FL
$761
Feb 11, 2025Exelixis Inc.
Feb 11, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Jan 28, 2025E.r. Squibb & Sons, L.l.c.
Jan 28, 2025
Compensation for services other than consulting (speaking, faculty)
OPDIVO · Oncology
$2,664
Jan 23, 2025E.r. Squibb & Sons, L.l.c.
Jan 23, 2025
Compensation for services other than consulting (speaking, faculty)
OPDIVO · Oncology
$2,664
Jan 9, 2025E.r. Squibb & Sons, L.l.c.
Jan 9, 2025
Compensation for services other than consulting (speaking, faculty)
OPDIVO · Oncology
$2,664

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Tennessee →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $2,689,577 in research payments for these studies, mostly to the institutions running them.

  • A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advanced Clear Cell Renal Cell Carcinoma ccRCC
    Merck Sharp & Dohme LLC
  • An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembro…
    Merck Sharp & Dohme LLC
  • Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
    Aveo Pharmaceuticals, Inc. · Completed · NCT04987203

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Nashville

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 22, 2024), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1609071349. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.